Form D · Biotechnology
Enobia Pharma Corp
Montreal, A8 · CIK 0001412621
Offering snapshot reported Aug 24, 2011 · SEC filing
- Reported sold
- $20M Offering amount: $40M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 9, 2011 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 24, 2011 | Initial | $20,000,000 | No comparison | 3 | SEC filing |
| Apr 1, 2011 | Initial | $15,000,000 | No comparison | 7 | SEC filing |
| Dec 13, 2010 | Amendment | $50,000,000 | $35,000,000vs Aug 28, 2009 | 8 | SEC filing |
| Aug 28, 2009 | Initial | $15,000,000 | No comparison | 8 | SEC filing |
| Sep 13, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $1.3M (estimated)
- Finders' fees
- $0
- Form D file number
- 021-164842
Subject to the terms and conditions of the stock purchase agreement, investors have committed to purchase $39,999,999.55 of securities in two equal tranches.
$650,000 is payable in connection with the first tranche of securities issued. In addition, Enobia Pharma Corp. has agreed to reimburse the placement agent for its out-of-pocket expenses up to a specified amount.
Source: Form D, filed Aug 24, 2011. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David Bonita | Director |
| Luc Cournoyer | Executive |
| Robert Heft | Director, Executive |
| Jeffrey Mack | Executive |
| Luc Mainville | Director |
| Richard Meadows | Director |
| Frederic Price | Director |
| Thomas Schuetz | Director |
| Jonathan Silverstein | Director |
| Eric L. Trachtenberg | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2901 Rachel St., Suite 23
Montreal, A8, H1W 4A4
Montreal, A8, H1W 4A4